Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T, Naito S, Hatakeyama S, Numakura K, Muto Y, Kato R, Kojima T, Kawasaki Y, Morozumi K, Kandori S, Kawamura S, Nishiyama H, Ito A, Habuchi T, Obara W, Ohyama C, Tsuchiya N, Kojima Y. Koguchi T, et al. Among authors: nishiyama h. Cancer Med. 2023 Nov;12(22):20677-20689. doi: 10.1002/cam4.6591. Epub 2023 Oct 31. Cancer Med. 2023. PMID: 37905674 Free PMC article.
C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R, Miyake M, Morizane S, Shimizu R, Teraoka S, Honda M, Iida K, Nishimura N, Sazuka T, Kimura T, Ito A, Shiga K, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Takenaka A. Nishikawa R, et al. Among authors: nishiyama h, nishiyama n. Int J Urol. 2023 Mar;30(3):299-307. doi: 10.1111/iju.15106. Epub 2022 Nov 30. Int J Urol. 2023. PMID: 36448522
Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors.
Sakka S, Kandori S, Kawai K, Kojima T, Nitta S, Chihara I, Nagumo Y, Kawahara T, Mathis BJ, Ishihara M, Shinohara N, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Sakka S, et al. Among authors: nishiyama h. Int J Urol. 2023 May;30(5):456-462. doi: 10.1111/iju.15155. Epub 2023 Feb 6. Int J Urol. 2023. PMID: 36746673
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi‑institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Kato R, et al. Among authors: nishiyama h. Int J Clin Oncol. 2023 May;28(5):726-727. doi: 10.1007/s10147-023-02331-z. Int J Clin Oncol. 2023. PMID: 37010622 Free PMC article. No abstract available.
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Numakura K, et al. Among authors: nishiyama h, nishiyama n. Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. Cancers (Basel). 2023. PMID: 37046663 Free PMC article.
Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study.
Koyama J, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Koyama J, et al. Among authors: nishiyama h. Int J Urol. 2023 Nov;30(11):1044-1050. doi: 10.1111/iju.15262. Epub 2023 Jul 31. Int J Urol. 2023. PMID: 37522577
1,092 results